Acquisitions27 Apr 2026, 07:31 am
Sun Pharma to Acquire Organon for $11.75 Billion
AI Summary
Sun Pharmaceutical Industries Ltd has signed a definitive agreement to acquire Organon & Co. for US$ 14.00 per share in an all-cash transaction, valuing Organon at an enterprise value of US$ 11.75 billion. This acquisition will make Sun Pharma a top 25 global pharmaceutical company with combined revenue of US$ 12.4 billion. The deal enables Sun Pharma's entry into biosimilars as a Top-10 global player and strengthens its position in Established Brands/Branded Generics and Women’s Health. The transaction has been approved by both Boards and is subject to regulatory and stockholder approvals.
Key Highlights
- Sun Pharma will acquire Organon for $14.00 per share in cash.
- The deal values Organon at an enterprise value of $11.75 billion.
- Combined revenue of Sun Pharma will be US$ 12.4 billion.
- Sun Pharma will become a top 3 company in global Women’s Health.
- Sun Pharma will become the 7th largest global biosimilar player.